Welcome to the e-CCO Library!

DOP39: Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme
Year: 2022
Source: ECCO'22
Authors: Higgins, P.(1);Colombel, J.F.(2);Reguiero, M.(3);Parkes, G.(4);Ilo, D.(5);Philips, C.(5);Yao, X.(6);Cheng, E.(6);Schreiber, S.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP39: Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Dignass, A.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Rubin, D.T.(5);Regueiro, M.(6);
Created: Friday, 14 July 2023, 10:43 AM
DOP39: Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Al Draiweesh*1,2, C. Ma1,3, M. Alkhattabi1, N. Chande1, B. G. Feagan1, J. C. Gregor1, R. Khanna1, P. Marotta1, A. Sandhu1, K. Qumosani1, A. Teriaky1, M. Brahmania1, V. Jairath1,4,5

Created: Friday, 22 February 2019, 9:41 AM
DOP39: Utilization and sustainability of biologics in UC - A nationwide study from the epi-IIRN
Year: 2021
Source: ECCO'21 Virtual
Authors: Atia, O.(1); Yogev, D.(1); Friss, C.(1); Focht, G.(1); Orlanski-Meyer, E.(1); Magen Rimon, R.(2); Ledderman, N.(3); Greenfeld, S.(4); Kariv, R.(5); Loewenberg Weisband, Y.(6); Gabay, H.(6); Nevo, D.(7); Matz, E.(8); Gorelik, Y.(9); Chowers, Y.(9); Dotan, I.(10);Turner, D.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP40 Does levels of concerns and expectations predict IBD disease status?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V. Pittet, Swiss IBD Cohort Study

Created: Thursday, 30 January 2020, 10:12 AM
DOP40: Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study
Year: 2021
Source: ECCO'21 Virtual
Authors: Zabana Abdo, Y.(1,2);Marín-Jiménez, I.(3);Rodríguez-Lago, I.(4);Vera, I.(5);Martín, M.D.(6);Guerra, I.(7);Gisbert, J.P.(2,8);Mesonero, F.(9);Benítez, O.(1);Taxonera, C.(10);Ponferrada-Díaz, Á.(11);Piqueras, M.(12);Lucendo, A.(2,13);Caballol, B.(2,14);Mañosa, M.(2,15);Martínez-Montiel, P.(16);Bosca-Watts, M.(17);Gordillo, J.(18);Bujanda, L.(19);Manceñido, N.(20);Martínez-Pérez, T.(21);López, A.(22);Rodríguez, C.(23);García-López, S.(24);Vega, P.(25);Rivero, M.(26);Melcarne, L.(27);Calvo, M.(28);Iborra, M.(2,29);Barreiro-de Acosta, M.(30);Arias, L.(31);Barrio, J.(32);Pérez, J.L.(33);Busquets, D.(34);Pérez-Martínez, I.(35);Navarro-Llavat, M.(36);Hernández, V.(37);Argüelles-Arias, F.(38);Domènech, E.(2,15);Esteve, M.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinib
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dubinsky, M.C.(1)*;D'Haens, G.(2);Dewit, O.(3);Juillerat, P.(4);Panaccione, R.(5);Fujii, T.(6);Lacerda, A.P.(7);Dubcenco, E.(7);Anyanwu, S.(7);Doshi, C.(7);Mallick, M.(7);Garrison, A.(7);Liu, J.(7);Loftus Jr, E.V.(8);
Created: Friday, 14 July 2023, 10:43 AM
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Meyer*1, J. Rudant2, J. Drouin2, A. Weill2, F. Carbonnel3, J. Coste2

Created: Friday, 22 February 2019, 9:41 AM
DOP40: Impact of corticosteroid usage on efficacy and safety outcomes in patients receiving upadacitinib for Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Raine, T.(1);Ishiguro, Y.(2);Rubin, D.(3);Finney-Hayward, T.(4);Dapo, I.(5);Phillips, C.(5);Cheng, E.(6);Targownik, L.(7);Loftus- Jr., E.V.(8);
Created: Friday, 11 February 2022, 3:52 PM
DOP41 Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Kabir1,2, K. Curtius3, I. Al-Bakir2,3,4, J. Hartono5, M. Johnson6, J.E. East6, J.O. Lindsay7,8, R. Vega9, S. Thomas-Gibson1,2, A. Hart2,4, T. Graham3, A. Wilson1,2

Created: Thursday, 30 January 2020, 10:12 AM
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sands, B.E.(1);Rubin, D.T.(2);Panés, J.(3);Gecse, K.B.(4);Leung, Y.(5);Goetsch, M.(6);Wang, W.(7);Shan, K.(8);Woolcott, J.(9);Smith, C.C.(9);Wosik, K.(10);Schreiber, S.W.(11)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP41: Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Vermeire, S.(1);Danese, S.(2);Zhou, W.(3);Klaff, J.(3);Ilo, D.(3);Yao, X.(4);Levy, G.(5);Higgins, P.D.R.(6);Loftus- Jr., E.V.(7);Panaccione, R.(8);
Created: Friday, 11 February 2022, 3:52 PM
DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Chiorean1, C. Su2, K. Matsuoka3, A. Orlando4, A. J. Thorpe2, C. I. Nduaka2, D. S. Chapman5, D. A. Woodworth2, N. Lawendy2, G. S. Friedman2, R. D. Cohen*6

Created: Friday, 22 February 2019, 9:41 AM
DOP41: Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study
Year: 2021
Source: ECCO'21 Virtual
Authors: Quaresma, A.B.(1);Damiao, A.O.M.C.(2);Coy, C.S.R.(3);Magro, D.O.(3);Valverde, D.A.(4);Panaccione, R.(5);Coward, S.B.(6);Ng, S.C.(7);Kaplan, G.G.(6);Kotze, P.G.(8)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP42 Impact of discontinuing thiopurines at anti-TNF initiation in inflammatory bowel disease: A nationwide Danish cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Bohn Thomsen1, R. Ungaro2, K. Allin3, G. Poulsen1, A. Mikael1, J.F. Colombel2, T. Jess1

Created: Thursday, 30 January 2020, 10:12 AM
DOP42: Dietary therapies induce rapid response and remission in active paediatric Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Sigall Boneh*1,2, J. Van Limbergen3, A. Assa4, R. Shaoul5, E. Wine6, P. Milman7, S. Cohen8, M. Kori9, S. Peleg10, A. On11, H. Shamaly12, L. Abramas1, A. Levine1,2

Created: Friday, 22 February 2019, 9:41 AM
DOP42: Disease course and clinical outcomes in Taiwan Crohn’s Disease patients with perianal fistula: A nationwide-based study
Year: 2021
Source: ECCO'21 Virtual
Authors: Weng, M.T.(1);Lin, K.L.(2);Chan, K.A.(3);Wei, S.C.(4)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP42: Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study
Year: 2022
Source: ECCO'22
Authors: Danese, S.(1);Panaccione, R.(2);D'Haens, G.(3);Peyrin-Biroulet, L.(4);Schreiber, S.(5);Kobayashi, T.(6);Gawdis-Wojnarska, B.(7);Korga, P.(8);Aguilar, H.(9);Sharkey, B.(10);Sreih, A.(11);Radosti, C.(10);Patel, A.(10);Canavan, J.(10);Rubin, D.(12);
Created: Friday, 11 February 2022, 3:52 PM
DOP42: Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chaparro, M.(1)*;Armuzzi, A.(2);Irving, P.M.(3,4);Allez, M.(5);Dubinsky, M.C.(6);Sands, B.E.(7);Goetsch, M.(8);Wang, W.(9);Shan, K.(10);Woolcott, J.(11);Bartolome, L.(12);Wosik, K.(13);Panaccione, R.(14);
Created: Friday, 14 July 2023, 10:43 AM
DOP43 The risk of extra-intestinal cancer in inflammatory bowel disease (IBD): A systematic review and meta-analysis of population-based cohort studies
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B.Z.S. Lo, M. Zhao, I. Vind, J. Burisch

Created: Thursday, 30 January 2020, 10:12 AM